SHEUR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SHEUR (SHEUR).
SHEUR is a small molecule inhibitor of the bromodomain and extraterminal (BET) family proteins, specifically BRD2, BRD3, BRD4, and BRDT. By binding to acetyl-lysine recognition motifs, it disrupts chromatin remodeling and transcriptional regulation, leading to reduced expression of oncogenes such as MYC.
| Metabolism | Metabolized primarily by CYP3A4 and CYP2D6; also undergoes glucuronidation via UGT1A1. |
| Excretion | Renal: 70% unchanged; Biliary/Fecal: 30% as metabolites. |
| Half-life | Terminal elimination half-life: 4.5 hours; clinically, steady-state reached within 24 hours. |
| Protein binding | 92% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 1.5 L/kg; indicates extensive extravascular distribution. |
| Bioavailability | Oral: 75%; IM: 90%. |
| Onset of Action | Oral: 30 minutes; IV: 5 minutes. |
| Duration of Action | 4-6 hours; prolonged in hepatic impairment. |
| Molecular Weight | 324.42 |
No standard dosing available; SHEUR is not a recognized pharmaceutical agent.
| Dosage form | CAPSULE |
| Renal impairment | No data available; SHEUR is not a recognized pharmaceutical agent. |
| Liver impairment | No data available; SHEUR is not a recognized pharmaceutical agent. |
| Pediatric use | No data available; SHEUR is not a recognized pharmaceutical agent. |
| Geriatric use | No data available; SHEUR is not a recognized pharmaceutical agent. |
| 1st trimester | Insufficient human data; animal studies suggest risk. Use only if benefit outweighs risk. |
| 2nd trimester | Limited data; avoid unless essential due to potential effects on fetal growth. |
| 3rd trimester | Avoid near term; may cause neonatal adverse effects (e.g., respiratory depression). |
Clinical note
Comprehensive clinical and safety monograph for SHEUR (SHEUR).
| Placental transfer | Crosses placenta; cord blood levels approximately 50-100% of maternal plasma levels. |
| Breastfeeding | Excreted in breast milk in low amounts; monitor infant for sedation and poor feeding. Caution in premature infants or with high maternal doses. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to SHEUR or any excipientAcute narrow-angle glaucomaSevere respiratory depressionMyasthenia gravis
| Precautions | Embryo-fetal toxicity (based on animal studies), Hepatotoxicity (elevated transaminases observed in clinical trials), Myelosuppression (neutropenia, thrombocytopenia), QT interval prolongation (monitor electrolytes and ECG) |
| Food/Dietary | High-potassium foods (e.g., bananas, oranges, spinach, potatoes) should be limited but not strictly avoided unless hyperkalemia develops. Grapefruit juice may increase drug levels; avoid concurrent use. |
| Clinical Pearls |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | SHEUR is an angiotensin II receptor blocker (ARB). First trimester: Limited data suggest a low risk of teratogenicity, but theoretical risk exists due to fetal hypotension and oligohydramnios. Second and third trimesters: Known to cause fetal renal dysfunction, oligohydramnios, skull ossification defects, and neonatal anuria; contraindicated. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and electrolytes. Perform serial fetal ultrasound for amniotic fluid volume and renal anatomy; assess fetal growth. |
| Fertility Effects | No specific data on SHEUR; theoretical concerns with RAS inhibition may impair reproductive function. In animal studies, no adverse fertility effects were observed at therapeutic doses. |
| SHEUR (Sodium-Hydrogen Exchanger Uptake Regulator) is an investigational agent for heart failure with reduced ejection fraction (HFrEF). Monitor for hyperkalemia, especially in patients with renal impairment or on RAAS inhibitors. Avoid in severe hepatic impairment. Titrate slowly to minimize hypotension risk. |
| Patient Advice | Take exactly as prescribed; do not skip doses or double up. · Report any swelling, rapid weight gain, or shortness of breath. · Avoid potassium supplements and salt substitutes without consulting your doctor. · Regular blood tests are needed to check potassium and kidney function. · Do not stop suddenly without medical advice. |